FATE
Fate Therapeutics, Inc.1.0900
-0.0300-2.68%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
125.73MP/E (TTM)
-Basic EPS (TTM)
-1.33Dividend Yield
0%Recent Filings
10-K
FY2025 results
Fate Therapeutics posted FY2025 results reflecting clinical momentum in its iPSC-derived cell therapy pipeline amid ongoing losses. No revenue figures or profitability metrics disclosed in the 10-K, with collaboration revenue from Ono trailing prior year due to a $5.0M clinical milestone hit in 2024. R&D expenses fell 20% y/y to $107.8M on lower stock comp and manufacturing costs, while G&A dropped 37% to $46.5M after patent savings; no Q4 breakdowns provided. Cash burn eased to $106M from operations, with $205M cash/investments at year-end supporting runway into 2027. No debt or capex trends detailed. Product candidates may fail clinical hurdles.
8-K
FT819 outpatient success, $205M cash
Fate Therapeutics reported Q4 and full-year 2025 results, highlighting FT819 outpatient CAR T-cell dosing in autoimmune patients across 16 sites, with 15 SLE and 4 SSc patients treated; one SSc patient showed disease improvements at 3 months using less-intensive chemo. FT836 yielded >50% CEA reduction in a CRC patient sans conditioning. Cash hit $205M, runway to 2027 after 30% opEx cut. Clinical data de-risks platform.
10-Q
Q3 FY2025 results
Fate Therapeutics narrowed Q3 losses to $32.3M ($0.27/share) from $47.7M ($0.40/share) y/y, with collaboration revenue dipping to $1.7M from $3.1M yet R&D expenses plunging 25% to $25.8M and G&A halved to $10.6M on restructuring cuts. Nine-month net loss improved to $103.9M ($0.88/share) from $134.1M ($1.19/share), driven by 19% lower opex to $118.3M; EPS reconciles to 118.7M diluted shares. Cash burn slowed with $82.8M YTD operating use versus $95.1M prior, leaving $225.7M in cash/investments and no debt. August 2025 restructuring trimmed workforce to stretch runway. Clinical delays from manufacturing complexities pose risks.
8-K
Q3 results, FT819 expansion
Fate Therapeutics reported Q3 2025 results with $226M cash extending runway through 2027, while securing UK MHRA and EU EMA nods to activate ex-US sites for FT819 autoimmune trials. First systemic sclerosis patient dosed fludarabine-free; FT836 solid tumor trial launched conditioning-free. Expenses dropped to $36.5M. Kamal Adawi named new CFO. Cash fuels milestones.
8-K
FT819 SLE data impresses
Fate Therapeutics disclosed Phase 1 data from 10 treatment-refractory SLE patients dosed with off-the-shelf FT819 CAR T-cells, showing rapid CD19+ B-cell depletion, naïve B-cell emergence, and significant SLEDAI-2K reductions—up to 16 points—in less-intensive or no conditioning regimens as of September 25, 2025 cutoff. No dose-limiting toxicities emerged; all discharged quickly. FT819 remodeled immune profiles effectively. Pivotal study targeted for 2026 under RMAT.
IPO
Employees
Sector
Industry
ACTU
Actuate Therapeutics, Inc.
6.96+0.10
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
CARM
Carisma Therapeutics, Inc.
0.05+0.00
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
FBRX
Forte Biosciences, Inc.
23.27+1.31
GTBP
GT Biopharma, Inc.
0.72+0.09
IMTX
Immatics N.V.
10.09+0.11
MRKR
Marker Therapeutics, Inc.
1.27-0.12
NKTR
Nektar Therapeutics
49.16-4.14
SANA
Sana Biotechnology, Inc.
5.00-0.08